Phase 3 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who are well enough to carry out daily activities with minimal limitations, and whose life expectancy is at least 12 weeks (confirm with trial site)
- People who have been diagnosed with a specific type of blood cancer called peripheral T-cell lymphoma (PTCL), confirmed through laboratory testing of a tissue sample, and whose subtype falls within a defined list that includes PTCL-NOS, AITL, ALCL (ALK+ or ALK-), Follicular T-cell lymphoma, PTCL-TFH, EATL, MEITL, NK/TCL, HSTCL, or SPTCL
- People whose lymphoma has stopped responding to, gotten worse during, or who could not tolerate at least one previous standard treatment
- People whose blood counts and organ functions (such as liver and kidneys) meet minimum health levels required by the trial
- People willing to follow specific birth control requirements during the trial
- People who are able to understand and sign the consent form and follow the trial's requirements
Who may not be able to join:
- People who have had or are currently receiving certain treatments that are not permitted under the trial rules
- People who are still experiencing side effects from a previous treatment that are rated above a moderate level of severity
- People whose lymphoma has spread to the brain or spinal cord
- People with serious heart or lung conditions
- People who need to take immune-suppressing medications, biological medicines, or certain anti-inflammatory drugs (NSAIDs)
- People with an active infection
- People who have had another cancer within the past five years
- People with poorly controlled digestive system problems that may affect how the body absorbs medication
- People with severe or poorly managed ongoing health conditions
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhao, Ruijin Hospital
Phone: 021-61095755
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free survival (PFS) assessed by the Independent Review Committee (IRC) according to Lugano 2014
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.